Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX) announced the pricing of a public offering of 6 million securities for gross proceeds of $66 million. The clinical-stage biopharmaceutical company priced 2,975,000 shares of common stock at $11.00 per share and 3,025,000 pre-funded warrants at $10.99 each.

The pre-funded warrants carry an exercise price of $0.01 per share. Eloxx expects to receive the full $66 million in gross proceeds before deducting underwriting discounts, commissions and offering expenses.

Trading on the Nasdaq Capital Market under the symbol "ELOX" is expected to begin June 9, 2026. The offering is scheduled to close June 10, 2026, subject to customary closing conditions.

Leerink Partners and Guggenheim Securities serve as joint bookrunning managers for the offering, while LifeSci Capital acts as passive bookrunner.

Eloxx develops small molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations. This process aims to enable production of full-length proteins.

The Securities and Exchange Commission declared the company's registration statement on Form S-1 effective June 8, 2026. The information is based on a company press release.